138 related articles for article (PubMed ID: 35013838)
1. Dose-escalated accelerated hypofractionation for elderly or frail patients with a newly diagnosed glioblastoma.
Perlow HK; Yaney A; Yang M; Klamer B; Matsui J; Raval RR; Blakaj DM; Arnett A; Beyer S; Elder JB; Ammirati M; Lonser R; Hardesty D; Ong S; Giglio P; Pillainayagam C; Goranovich J; Grecula J; Chakravarti A; Gondi V; Brown PD; Palmer JD
J Neurooncol; 2022 Jan; 156(2):399-406. PubMed ID: 35013838
[TBL] [Abstract][Full Text] [Related]
2. Accelerated hypofractionated radiation for elderly or frail patients with a newly diagnosed glioblastoma: A pooled analysis of patient-level data from 4 prospective trials.
Perlow HK; Prasad RN; Yang M; Klamer B; Matsui J; Marrazzo L; Detti B; Scorsetti M; Clerici E; Arnett A; Beyer S; Ammirati M; Chakravarti A; Raval RR; Brown PD; Navarria P; Scoccianti S; Grecula JC; Palmer JD
Cancer; 2022 Jun; 128(12):2367-2374. PubMed ID: 35315512
[TBL] [Abstract][Full Text] [Related]
3. Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years.
Ohno M; Miyakita Y; Takahashi M; Igaki H; Matsushita Y; Ichimura K; Narita Y
Radiat Oncol; 2019 Nov; 14(1):200. PubMed ID: 31718669
[TBL] [Abstract][Full Text] [Related]
4. Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial).
Mallick S; Kunhiparambath H; Gupta S; Benson R; Sharma S; Laviraj MA; Upadhyay AD; Julka PK; Sharma D; Rath GK
J Neurooncol; 2018 Oct; 140(1):75-82. PubMed ID: 29936695
[TBL] [Abstract][Full Text] [Related]
5. Accelerated hyperfractionated radiochemotherapy with temozolomide is equivalent to normofractionated radiochemotherapy in a retrospective analysis of patients with glioblastoma.
Lewitzki V; Klement RJ; Kosmala R; Lisowski D; Flentje M; Polat B
Radiat Oncol; 2019 Dec; 14(1):227. PubMed ID: 31831026
[TBL] [Abstract][Full Text] [Related]
6. Standard dose and dose-escalated radiation therapy are associated with favorable survival in select elderly patients with newly diagnosed glioblastoma.
Jackson WC; Tsien CI; Junck L; Leung D; Hervey-Jumper S; Orringer D; Heth J; Wahl DR; Spratt DE; Cao Y; Lawrence TS; Kim MM
J Neurooncol; 2018 May; 138(1):155-162. PubMed ID: 29388034
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of hypofractionated radiation therapy in elderly patients with newly diagnosed glioblastoma with poor prognosis.
Navarria P; Pessina F; Cozzi L; Tomatis S; Reggiori G; Simonelli M; Santoro A; Clerici E; Franzese C; Carta G; Conti Nibali M; Bello L; Scorsetti M
Tumori; 2019 Feb; 105(1):47-54. PubMed ID: 30131010
[TBL] [Abstract][Full Text] [Related]
8. A randomized phase III study of short-course radiotherapy combined with Temozolomide in elderly patients with newly diagnosed glioblastoma; Japan clinical oncology group study JCOG1910 (AgedGlio-PIII).
Arakawa Y; Sasaki K; Mineharu Y; Uto M; Mizowaki T; Mizusawa J; Sekino Y; Ono T; Aoyama H; Satomi K; Ichimura K; Kinoshita M; Ohno M; Ito Y; Nishikawa R; Fukuda H; Nishimura Y; Narita Y;
BMC Cancer; 2021 Oct; 21(1):1105. PubMed ID: 34654402
[TBL] [Abstract][Full Text] [Related]
9. Hypofractionated radiotherapy with simultaneous integrated boost (SIB) plus temozolomide in good prognosis patients with glioblastoma: a multicenter phase II study by the Brain Study Group of the Italian Association of Radiation Oncology (AIRO).
Scoccianti S; Krengli M; Marrazzo L; Magrini SM; Detti B; Fusco V; Pirtoli L; Doino D; Fiorentino A; Masini L; Greto D; Buglione M; Rubino G; Lonardi F; Migliaccio F; Marzano S; Santoni R; Ricardi U; Livi L
Radiol Med; 2018 Jan; 123(1):48-62. PubMed ID: 28879459
[TBL] [Abstract][Full Text] [Related]
10. Radiation therapy dose escalation for glioblastoma multiforme in the era of temozolomide.
Badiyan SN; Markovina S; Simpson JR; Robinson CG; DeWees T; Tran DD; Linette G; Jalalizadeh R; Dacey R; Rich KM; Chicoine MR; Dowling JL; Leuthardt EC; Zipfel GJ; Kim AH; Huang J
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):877-85. PubMed ID: 25257812
[TBL] [Abstract][Full Text] [Related]
11. The role of radiation therapy in treatment of adults with newly diagnosed glioblastoma multiforme: a systematic review and evidence-based clinical practice guideline update.
Ziu M; Kim BYS; Jiang W; Ryken T; Olson JJ
J Neurooncol; 2020 Nov; 150(2):215-267. PubMed ID: 33215344
[TBL] [Abstract][Full Text] [Related]
12. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
13. Interim Results of a Phase II Study of Hypofractionated Radiotherapy with Concurrent Temozolomide Followed by Adjuvant Temozolomide in Patients over 70 Years Old with Newly Diagnosed Glioblastoma.
Yusuf M; Ugiliweneza B; Amsbaugh M; Boakye M; Williams B; Nelson M; Hattab EM; Woo S; Burton E
Oncology; 2018; 95(1):39-42. PubMed ID: 29694955
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy combined with temozolomide for the postoperative treatment of glioblastoma multiforme: a single-institution experience.
Zhong L; Chen L; Lv S; Li Q; Chen G; Luo W; Zhou P; Li G
Radiat Oncol; 2019 Jun; 14(1):104. PubMed ID: 31196126
[TBL] [Abstract][Full Text] [Related]
15. Hypofractionated radiation therapy versus chemotherapy with temozolomide in patients affected by RPA class V and VI glioblastoma: a randomized phase II trial.
Pedretti S; Masini L; Turco E; Triggiani L; Krengli M; Meduri B; Pirtoli L; Borghetti P; Pegurri L; Riva N; Gatta R; Fusco V; Scoccianti S; Bruni A; Ricardi U; Santoni R; Magrini SM; Buglione M
J Neurooncol; 2019 Jul; 143(3):447-455. PubMed ID: 31054101
[TBL] [Abstract][Full Text] [Related]
16. Hypofractionated versus standard radiation therapy with or without temozolomide for older glioblastoma patients.
Arvold ND; Tanguturi SK; Aizer AA; Wen PY; Reardon DA; Lee EQ; Nayak L; Christianson LW; Horvath MC; Dunn IF; Golby AJ; Johnson MD; Claus EB; Chiocca EA; Ligon KL; Alexander BM
Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):384-9. PubMed ID: 25841623
[TBL] [Abstract][Full Text] [Related]
17. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.
Malmström A; Grønberg BH; Marosi C; Stupp R; Frappaz D; Schultz H; Abacioglu U; Tavelin B; Lhermitte B; Hegi ME; Rosell J; Henriksson R;
Lancet Oncol; 2012 Sep; 13(9):916-26. PubMed ID: 22877848
[TBL] [Abstract][Full Text] [Related]
18. A Phase 2 Trial of Neoadjuvant Temozolomide Followed by Hypofractionated Accelerated Radiation Therapy With Concurrent and Adjuvant Temozolomide for Patients With Glioblastoma.
Shenouda G; Souhami L; Petrecca K; Owen S; Panet-Raymond V; Guiot MC; Corredor AG; Abdulkarim B
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):487-494. PubMed ID: 28011051
[TBL] [Abstract][Full Text] [Related]
19. Feasibility evaluation of hypofractionated radiotherapy with concurrent temozolomide in elderly patients with glioblastoma.
Uto M; Mizowaki T; Ogura K; Arakawa Y; Mineharu Y; Miyamoto S; Hiraoka M
Int J Clin Oncol; 2016 Dec; 21(6):1023-1029. PubMed ID: 27384182
[TBL] [Abstract][Full Text] [Related]
20. Hypofractionated radiation therapy and temozolomide in patients with glioblastoma and poor prognostic factors. A prospective, single-institution experience.
Jablonska PA; Diez-Valle R; Pérez-Larraya JG; Moreno-Jiménez M; Idoate MÁ; Arbea L; Tejada S; Garcia de Eulate MR; Ramos L; Arbizu J; Domínguez P; Aristu JJ
PLoS One; 2019; 14(6):e0217881. PubMed ID: 31170245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
